Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to report earnings of ($0.24) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.29). Tandem Diabetes Care reported earnings of ($1.23) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 80.5%. The firm is scheduled to issue its next earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.83) to ($2.87). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.16) to ($0.58). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.28). The firm had revenue of $46.30 million during the quarter, compared to the consensus estimate of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. Tandem Diabetes Care’s revenue was up 71.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.09) EPS.
Tandem Diabetes Care stock opened at $39.56 on Monday. The stock has a market capitalization of $2.13 billion, a P/E ratio of -3.07 and a beta of 0.53. Tandem Diabetes Care has a 12-month low of $2.14 and a 12-month high of $52.55.
In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff sold 198,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $37.01, for a total transaction of $7,327,980.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard P. Valencia bought 1,300 shares of Tandem Diabetes Care stock in a transaction on Monday, November 5th. The shares were bought at an average price of $37.75 per share, for a total transaction of $49,075.00. The disclosure for this purchase can be found here. 9.30% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE boosted its holdings in Tandem Diabetes Care by 397.8% during the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after buying an additional 1,989 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of Tandem Diabetes Care by 1,921.6% during the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after purchasing an additional 2,575 shares during the period. Wells Fargo & Company MN raised its position in shares of Tandem Diabetes Care by 11.3% during the third quarter. Wells Fargo & Company MN now owns 26,968 shares of the medical device company’s stock worth $1,155,000 after purchasing an additional 2,734 shares during the period. Rhumbline Advisers raised its position in shares of Tandem Diabetes Care by 6.8% during the third quarter. Rhumbline Advisers now owns 45,756 shares of the medical device company’s stock worth $1,960,000 after purchasing an additional 2,910 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth about $174,000. Hedge funds and other institutional investors own 62.80% of the company’s stock.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.